| The Life Extension Foundation Forums > LEF Public Forums > Social/Political Aspects > F.D.A. Warning Is Issued On Anemia Drugs' Overuse | Forum Quick Jump
|
|  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 5/11/2007 7:01 PM (GMT -4) |   |
The New York Times article states that the drugs, given by injection, have been heavily advertised, and there is evidence that they have been overused, in part because oncologists can make money by using more of the drug. http://query.nytimes.com/gst/fullpa...750C0A9619C8B63According to Dr. John Glaspy, director of UCLA's Outpatient Oncology Clinic, one complicating factor, experts say, is that oncologists make significant revenue buying cancer drugs from manufacturers and charging patients a higher price for receiving the drugs in their offices. That profit motive could influence some doctors' decisions. However, patients with anemia, which can cause sluggishness in its early stages and can be fatal in advanced phases, can get blood transfusions, typically every few weeks, instead of using EPO. Len Lichtenfeld, deputy chief medical officer for the Atlanta-based American Cancer Society, told United Press International, "Probably more than a billion dollars is spent on erythropoietin each year, which makes it one of the most expensive cancer drugs." A six-month course of treatment can cost more than $10,000 per patient. In panel discussion that highlighted the 12th annual conference of the National Comprehensive Cancer Network, Lee Newcomer, former chief medical officer and currently an executive with Minneapolis-based United Health Group, pointed out that in reviewing records of patients who were prescribed the drug erythropoietin, said that 44% of those patients had blood work-ups that would indicate they were not anemic. http://www.sciencedaily.com/upi/ind...ts-analysis.xmlU.S. Oncology takes a hit! Reports first-quarter net loss. U.S. Oncology said a number of factors impacted the results, including reduced pre-tax income due to lower use of certain supportive care drugs used to treat cancer-induced anemia: and the discontinuation of the Medicare Demonstration Project. http://www.bizjournals.com/houston/...html?from_rss=1The Senate Finance Committee Chairman found that the value of the approximately $300 million-a-year Medicare Demonstration Project to report on a patient's level of nausea, vomiting, pain and fatigue was for nothing. CMS paid chemotherapy providers $130 per report, per infusional-chemotherapy recipient, on a patient's level of nausea, vomiting, pain and fatigue. However, HHS' inspector general's office found these providers were being paid an extra $130 to simply forward the data that was already collected. A continuance of the Medicare Demonstration Project would have exacerbated existing economic and clinical problems instead of resolving them by increasing the temptations for physicians to overuse injectable drugs and promise to aggravate the ecnomic problems Congress attempted to fix with the new Medicare law. U.S. Oncology Under the Gun U.S. Oncology reports two seeming unrelated bits in their latest SEC Form 10-K. One note say cancer patients are suddenly using a lot less anemia drugs, and as a result U.S. Oncology will bank $8-10 million a year less than expected. The second note says that in 2005 the company was subpoenaed by the U.S. Department of Justice about contracts and relationships with pharmaceutical companies. Coincidence? http://www.prnewswire.com/cgi-bin/s...004579964&EDATEFederal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians’ offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors’ purchase price. It's still your mother's chemotherapy drug concession. Although the new Medicare bill tried to curtail the drug concession, private insurers still go along with it. What needs to be done is to remove the profit incentive from the choice of drug treatments. Let's take physicians out of the retail pharmacy business and let them be doctors again!!!
Post Edited (gdpawel) : 11/17/2007 3:31:01 AM (GMT-5) | | Back to Top | | |
 |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 5/14/2007 10:30 AM (GMT -4) |   |
New studies have raised questions whether these drugs might actually be harming them. Those study results suggest the drugs may make the cancer worse.
Dr. Eric Winer, director of the breast oncology center at Dana-Farber Cancer Institute feels that these drugs are presumed to be entirely safe, given for supportive care and to improve quality of life, but not actually used to treat cancer. But the drugs may have been used in ways not approved on the labels.
A study published in the New England Journal of Medicine last November found that patients treated aggressively with Procrit had a higher risk of heart problems or death than those treated less aggressively.
Amgen, the maker of Aranesp, announced late January that in one of its clinical trials, patients were more likely to die than those getting a placebo. The trial was testing the drug in patients whose anemia was caused by the cancer itself, not by chemotherapy. While a Danish study in patients with head and neck cancer had to be stopped early because the cancer seemed to recur more in patients being treated with Aranesp.
In February, the Journal of Clinical Oncology published a paper describing a small Canadian trial in lung cancer patients had also been stopped early because those getting Eprex were dying sooner. While Roche suspended patient enrollment in a lung cancer trial comparing its Cera against Amgen's Aranesp because of greater than expected number of deaths in at least some of the arms of the trial.
It is not known why the drugs may cause these problems. It is known that raising hemoglobin levels too high increases the risk of blood clots. While most of these trials did aim to increase hemoglobin above the levels recommended in the drugs' labels, that was not the case with Amgen's own trial.
There is some evidence that clots were not the problem in the trials, but that Epo may spur tumor growth. Some studies suggest that certain tumor cells, such as those in head and neck cancer, have proteins on their surface that bind to Epo. When that happens, it sets off a cascade of reactions spurring growth.
Studies done by Dr. Jennifer R. Grandis, professor at the University of Pittsburgh, found enough biologic possibility that they can serve as a growth factor for the cancer cell.
Concerns about the safety of the drugs for cancer were first raised in 2003 by two studies that showed patients getting Epo had worse outcomes. Until then, these drugs had shown signs that they could improve the quality of life for cancer patients, even though their safety labeling has already been revised three times since 1997.
Whiz bang therapies often get a pass on toxicities because they are just so darn cool. The problem is that few drugs work the way we think and few physicians/scientists take the time to think through what it is they are using them for.
Source: TherapeuticsDaily
Post Edited (gdpawel) : 11/17/2007 3:31:23 AM (GMT-5) | | Back to Top | | |
 |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 10/6/2007 1:06 PM (GMT -4) |   |
EPO is a "natural" substance made by the kidney. It stimulates the bone marrow to make red blood cells. Healthy adults are usually at about 15 grams a deciliter. For cancer patients, upping the production of "natural" EPO via our hair follicles could be very beneficial.
Increasing the hemoglobin level above 12 is very risky with "pharmaceutical" EPO. Pharmaceutical EPO makes sludgy blood. When normal people take it, their blood gets too thick and they die of heart attacks and strokes.
The anemia drugs, which boosts patients' counts of hemoglobin (a protein that carries oxygen in the blood), raise the danger of heart attacks, strokes and death at "high" doses. The FDA has said there is "serious" cardiovascular risks for patients who take "higher than recommended" doses of these drugs.
These anemia drugs are approved to treat patients whose weakness and fatigue is caused by chronic kidney disease or by the side effects of cancer chemotherapy. They stimulate production of oxygen-carrying red blood cells, which can boost patients' energy and strength, if red blood cells are brought back to "normal" levels.
The issue is over the drugs' safety on how big a dose to use to boost concentrations of hemoglobin. The FDA-approved level is doses sufficient to increase hemoglobin to a maximum of 12 grams a deciliter.
The adage of some physicians is that if some improvement in hemoglobin was good, higher levels of hemoglobin would even be better. However, clinical trials have shown the drugs can reduce the need for blood transfusions and improve the quality of life "when used within the original dosing range."
New studies have raised questions whether these drugs might be harming patients. Those study results suggest the drugs may make the cancer worse. One such study published in the New England Journal of Medicine found that patients treated aggressively with Procrit had a higher risk of heart problems or death than those treated less aggressively.
And now there is emerging evidence that pharmaceutical EPO can feed the growth of tumors in cancer patients (it IS a "growth factor" afterall). A “growth factor” is about twenty small proteins that attach to specific receptors on the surface of stem cells in bone marrow and promote differentiation and maturation of these cells into morphotic constituents of blood. And blood is a circulating tissue composed of fluid plasma and cells (red blood cells, white blood cells, platelets). Problems with blood composition or circulation can lead to downstream tissue (which is made up of cells) dysfunction.
EPO manufacturers and cancer societies have at least two lawmakers in their pocket in regards to anemia drugs. Representatives Anna Eshoo (D-Calif.) and Mike Rogers (R-Mich.) introduced legislation that would overturn a decision by the Centers for Medicare and Medicaid Services (CMS) to limit the circumstances under which Medicare will pay for anti-anemia treatments of cancer patients using pharmaceutical EPO. Legislation takes the form of a Congressional Review Act joint resolution, a rarely used tool that allows Congress to overturn regulatory decisions made by federal agencies.
The lawmakers allies in Congress, the American Society for Clinical Oncology, the American Society of Hematology and the cancer treatment center company US Oncology also are participating in the effort. The CMS policy affects the use of the drugs only for cancer patients, hence the fraternal organizations' involvement. The resolution is meant to serve as a reminder that special interests with a stake in Medicare coverage have friends in Congress.
Congress has been intensifying its scrutiny of Medicare spending on pharmaceutical EPO, which resprsents the single largest drug expense for the program. Some other key lawmakers view the manufacturers of EPO skeptically, citing Medicare's rising spending on the drugs. Earlier in the year, U.S. Oncology reported in their first quarter SEC Form 10-K report that cancer patients are suddenly using a lot less anemia drugs and as a result U.S. Oncology will bank $8-10 million a year less than expected.
Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or cancer centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price.
It's time to take medical oncologists out of the retail pharmacy business and force them to be cancer "doctors" again! | | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/7/2007 11:56 PM (GMT -4) |   | | | |
 |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 10/14/2007 8:51 PM (GMT -4) |   | |
My little internet blog groupie Michelle (hchcec) has given us a campaign, supported and funded by Amgen.
The ProtectCancerPatients.org website is a campaign supported and funded by Amgen - one of the manufacturers of pharmaceutical EPO.
The Michelle (hchcec) character has been posting on the internet that an Anemia drug study shows no link to tumor growth. However, the study does not say anything about anemia drugs not showing a link.
The study "suggests" that extended doses of Amgen's anemia drug Aranesp, when paired with chemotherapy treatment, work as well as weekly doses (this does not say anything that anemia drugs are not a growth factor).
The data from the study showed that results from two combined studies indicate patients treated with the drug needed fewer blood transfusions without serious impacts (this does not say anything that anemia drugs are not a growth factor).
The company said, "These analyses do not suggest a negative impact on overall survival or progression-free survival between patients receiving chemotherapy treatment with aranesp and those that did not receive Aranesp." (this does not say anything that anemia drugs are not a growth factor)
And who is the "sponsor" of this study, and six other trials of Aranesp to treat anemia as a result of chemotherapy??? Amgen!!! Of course!!!
| | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/16/2007 3:03 PM (GMT -4) |   | OOPS! Pawelski misinterprets and misinforms again. Nothing new for the internet's most prolific cancer fearmonger. He won't be happy until you are as unhappy as he is . He has a grudge, you know.
The study conclusion: This reasonably large randomized trial does NOT show an adverse effect of Aranesp on progression-free survival of patients with extensive stage SCLC receiving chemotherapy. These data would suggest that Aranesp did NOT stimulate cancer growth in this setting.
Here's another for ya, G.P. http://mct.aacrjournals.org/cgi/content/full/5/2/347 Let's see if you can spin this one so as to cause fear in cancer patients. (Methinks Pawelski wants you to try homeopathy for your cancer :wink: )
Pawelski's logical fallacy of the day: The Michelle (hchcec) character has been posting on the internet that an anemia drug study shows no link to tumor growth. However, the study does not say anything about anemia drugs not showing a link.
That's like me saying there's no evidence for Bigfoot. Then Pawelski then states: "there's no evidence Bigfoot doesn't exist." Sorry Mr. Fearmonger. It's up to you to prove Bigfoot (anemia drug tumor growth link) exists, no for me to prove it doesn't.
So illogical. But, remember, G.P preys on your emotions. Logic is left in the dust.
hchcec | | Back to Top | | |
  |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/16/2007 5:28 PM (GMT -4) |   | "epoetins have not been shown to improve overall survival or THE RISK OF TUMOR PRGRESSION." http://www.pharmaceutical-business-review.com/article_news.asp?guid=D4FA4A37-60FC-44B4-BC56-39D3B93B9DAB
Sadly, the emotional G. Pawelski would have you believe that your cancer will grow when you take your anemia drug. He's the internet's #1 cancer fearmonger and he wants you to fear your cancer AND your treatment. He won't be happy until you are as unhappy as he is. He has a grudge and he wants YOU to feel unhappy, too.
We know the anemia drugs don't improve survival. That's not why they're taken. But, he wants you to think they'll make your cancer grow. This prolific internet huckster (do a google search on pawelski and cancer) misinforms (as he has done repeatedly here) and misinterprets. He has no science education, has never worked in a lab, and has never treated a patient. Keep that in mind. | | Back to Top | | |
 |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 10/16/2007 6:48 PM (GMT -4) |   | A growth factor is about twenty small proteins that attach to specific receptors on the surface of stem cells in bone marrow and promote differentiation and maturation of these cells into morphotic constituents of blood. And blood is a circulating tissue composed of fluid plasma and cells (red blood cells, white blood cells, platelets). Problems with blood composition or circulation can lead to downstream tissue (which is made up of cells) dysfunction. If pharmaceutical EPO stimulates the bone marrow to make red blood cells, it could feed the growth of tumors in cancer patients.
A study published in the journal of the American Cancer Society, led by Jeffrey Peppercorn of the University of North Carolina Lineberger Cancer Center, along with three researchers at the Dana-Farber Cancer Institute, found that 84% of trials with pharmaceutical-company involvement showed positive results, compared to 54% for trials without industry backing. Another previous study in oncology, looking at multiple myeloma, found that pharmaceutical studies reported positive results in 74% of trials compared to 47% of non-industry-sponsored trials.
An increasing number of drug studies are developed through collaborations between academic medical centers and drug companies. In fact, pharmaceutical-industry investment in research exceeds the entire operating budget of the NIH. It is important to understand the influence that industry involvement may have on the nature and direction of cancer research. Studies backed by pharmaceutical companies were significantly more likely to report positive results.
More must be spent on analyzing drug data, we also need larger and more detailed studies to figure out why there is an association between pharmaceutical involvement and positive results. Some of the connection between industry and positive results may be because industry focuses on drug development and they do it well.
However, drugmakers are going directly to the consumer at a time when their products are indeed at the margins of pharma-based medicine. On one hand, pharmaceuticals advertise extensively and the advertising is manipulative in the extreme. On the other hand, even NCI-designated cancer centers do this sort of direct to consumer, hard sell advertising. And in cancer medicine, the media advertising is no more misleading than the one-on-one communication which often goes on between a chemotherapy candidate and an oncologist.
When an oncologist recommends a treatment the reason behind the recommendation may be complex. It can be a result of the doctor's training and experience in combination with the investments made by the hospital or the doctors own research interests or their financial relationships with various outside entities. In short, a patient and their family must be their own best advocate and get at the heart as to why a specific treatment regimen is being suggested. Don't be afraid to ask questions to make informed treatment decisions!
http://jco.ascopubs.org/cgi/content/full/25/25/e31
Post Edited (gdpawel) : 10/16/2007 7:27:16 PM (GMT-4) | | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/17/2007 10:33 AM (GMT -4) |   | Notice, as is usual with the internet's most notorious fearmonger, no, zero, zilch, nada data to prove his layman's thesis that EPO causes tumor growth.
But, he'll say "it could feed the growth of tumors in cancer patients," just to frighten you. As if your cancer isn't frightening enough. I think this guy starred in Halloween 5. | | Back to Top | | |
  |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/18/2007 11:06 AM (GMT -4) |   | Notice no evidence that anemia drugs make tumors grow, the internet's most notorious fearmonger has yet to indicate so.
The whole "pharma shill" attack is very typical of the alternative medicine crowd. They won't address their false statement and their wild theories, as he has done here. They'll just blame western medicine, oncologists, the scientific method, etc. Take what these woomeisters take with a grain of salt. | | Back to Top | | |
  |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 10/18/2007 2:52 PM (GMT -4) |   | There is enough evidence to suggest that we do not fully use what is known to be effective treatment of cancer. There is an appalling lack of information on the quality of care for most cancers and efforts to measure quality in cancer care are embryonic at best.
Early detection and biomarkers are where cancer research resources need to be funneled. But the money seems to go towards developing expensive, last-ditch treatment for desperate, dying people willing to spend any amount of money to stay alive. Even if it's for 1.6 months longer.
That's the average number of months, with a plethora of sides effects, for Bristol-Myers Squibb's new drug, Ixempra. What the good people over at the WSJ Health Blog tell us, at a time when "targeted" cancer treatments like Herceptin and Gleevec are all the rage, chemotherapy can seem like a retro blunderbuss.
The FDA's approval of a Bristol-Myers Squibb drug harkens back to the old-school for breast cancer patients who aren't responding to other treatments. Another example of new cancer drug applications for "me-too" drugs that might show only miniscule clinical improvement in trials, yet they somehow gain approval.
Since they are "marketed" as if they are important new breakthroughs, they have very high prices. Yet for pharaceutical shills, you "can't leave home without it."
It's a new drug for patients who have failed two or three other chemo drugs. For use by patients who have tried - without success - prior types of treatment? Why not give them the "right" drug or combinations the "first"time around?
Why not have a "functional" bio-marker to aid the physician in selecting an effective agent or combination of agents the first time around, to avoid exposing the patient to ineffective harmful drugs, reducing the cost and decreased quality of life assoicated with ineffective treatment?
Everyone would agree that the earlier in the course of the disease that the most active treatment is given, the better the result for the patient. But to pharmaceutic shills, it would be tantamount to "fear mongering" cancer patients!
The FDA says that there is no evidence that pharmaceutical EPO results in improved survival, "tumor control," health-related quality of life at any hemoglobin level in cancer patients undergoing chemotherapy. Pharmaceutical EPO was approved based on its effectiveness in reducing the need for red blood cell transfusions.
If ASCO has a complaint about CMS payment policy, it should provide evidence to the physicians at that agency who made the recent NCD decision on pharmaceutical EPO, which is in line with the FDA label. Just be sure to give the infamous pharmaceutical shill a copy of it, so she won't read it. She won't read anyone else's evidence anyway. She'll just tow the pharma-based line.
Post Edited (gdpawel) : 11/17/2007 3:32:09 AM (GMT-5) | | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/18/2007 3:32 PM (GMT -4) |   | where's the epo/tumor growth link info. Pawelski?
(The internet's most notorious antiscientific method cancer fearmonger won't address the question. He'll hammer away at science, thrill you with his conspiracy theories, then find the next support site to do the same thing.)
He refuses to answer the question. | | Back to Top | | |
 |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 10/18/2007 6:32 PM (GMT -4) |   | |
Am I the FDA Michelle? Or is the FDA conspiring to get you too?
The FDA backed CMS' National Coverage Decision (NCD), which limited use of the drugs because they have been shown to spur tumor growth.
The FDA has stated that the health risks associated with the use of pharmaceutical EPO (ESAs) for cancer patients include: Promotion of tumor growth in patients with advanced breast, head and neck, lymphoid, and non-small cell lung malignancies in studies adminstered EPO to target a hemoglobin of >12 g/dL, and have not been excluded with lower target hemoglobin levels.
The FDA believes that the approved labeling and CMS's National Coverage Decision are generally consistent in their recommendations regarding the use of pharmaceutical EPO in patients with cancer undergoing chemotherapy.
FDA's approved labeling recommends use of the lowest dose necessary to avoid the need for blood transfusions and transfusions are not normally given to patients whose hemoglobin is 10 g/dL or higher. The recommendation in the approved labeling that the hemoglobin not exceed 12 g/dL in cancer patients "is intended as an upper safety limit, not a target for therapy."
A “growth factor” is about twenty small proteins that attach to specific receptors on the surface of stem cells in bone marrow and promote differentiation and maturation of these cells into morphotic constituents of blood. And blood is a circulating tissue composed of fluid plasma and cells (red blood cells, white blood cells, platelets).
Problems with blood composition or circulation can lead to downstream tissue (which is made up of cells) dysfunction. If pharmaceutical EPO stimulates the bone marrow to make red blood cells, it could feed the growth of tumors in cancer patients.
Again, if ASCO has a complaint about CMS payment policy, it should provide evidence to the physicians at that agency who made the decision. There is no evidence that pharmaceutical EPO results in improved survival, "TUMOR CONTROL," health-related quality of life at any hemoglobin level in cancer patient undergoing chemotherapy.
Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment.
The anemia drugs are injected or given intravenously in physicians’ offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors’ purchase price.
It's still your mother's chemotherapy concession. Although the new Medicare bill tried to curtail the drug concession, private insurers still go along with it. What needs to be done is to remove the profit incentive from the choice of drug treatments. Let's take physicians out of the retail pharmacy business and force them to be doctors again!!!
| | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/18/2007 9:18 PM (GMT -4) |   | OH MY, Pawelski. He does it again. He links to some FDA guy, BUT HE CAN'T FIND ANY STUDIES TO PROVE HIS THEORY.
Pawelski, the internet huckster of unproven cancer remedies, can't find the data to prove his theory. His MO is to read something on the internet, go to every support group to frighten cancer patients (despicable), yet never produces the data. Why? Because he hates the scientific method. He's not a scientist (obvious), never treated a patient, never worked in a lab.
He's the faceless star of the internet, who's sole goal is to frighten cancer patients.
Where's the data, Pawelski? | | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/19/2007 10:38 AM (GMT -4) |   | | | |
  |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/19/2007 7:42 PM (GMT -4) |   | OOPS! There goes Pawelski AGAIN. NO EVIDENCE OF HIS EPO/TUMOR LINK. HE'S LAZY. HE RELIES ON ONE FDA GUY (OF COURSE HE'LL'' TRASH ANY SCIENTIST, EVEN ONE FROM THE FDA IF HE OR SHE DOESN'T AGREE WITH HIM.)
He says I attack. OK, Pawrlski. I do attack your laziness. So, where's your data. You've probably gone to countless support group sites to espouse your theory. But, you have no evidence.
Where is it? | | Back to Top | | |
 |  gpawelski Registered Member
       Date Joined May 2001 Total Posts : 117 | Posted 10/22/2007 11:39 AM (GMT -4) |   |
EPO manufacturers and cancer societies have at least two lawmakers in their pocket in reference to anemia drugs. Representatives Anna Eshoo (D-Calif.) and Mike Rogers (R-Mich.) introduced legislation that would overturn a decision by the Centers for Medicare and Medicaid Services (CMS) to limit the circumstances under which Medicare will pay for anti-anemia treatments of cancer patients using pharmaceutical EPO. Legislation takes the form of a Congressional Review Act joint resolution, a rarely used tool that allows Congress to overturn regulatory decisions made by federal agencies.
The lawmakers allies in Congress, the American Society for Clinical Oncology, the American Society of Hematology and the cancer treatment center company US Oncology also are participating in the effort. The CMS policy affects the use of the drugs only for cancer patients, hence the fraternal organizations' involvement. The resolution is meant to serve as a reminder that special interests with a stake in Medicare coverage have friends in Congress.
Congress has been intensifying its scrutiny of Medicare spending on pharmaceutical EPO, which represents the single largest drug expense for the program. Some other key lawmakers view the manufacturers of EPO skeptically, citing Medicare's rising spending on the drugs. Earlier in the year, U.S. Oncology reported in their first quarter SEC Form 10-K report that cancer patients are suddenly using a lot less anemia drugs and as a result U.S. Oncology will bank $8-10 million a year less than expected.
CMS Wants More Proof Before Reconsidering ESA Decision
Groups Ask Congress Not To Intervene In CMS Decision On Anemia Drugs
| | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/22/2007 2:57 PM (GMT -4) |   | This is getting boring, Pawelski. Your laziness is a concern.
Where's your data? You've probably gone to countless support group sites to espouse your EPO/tumor theory. You've done it here. But, you have no evidence.
Where is it? C'mon, ol' pal. Do your research before you go to your next support group to scare women with ovarian cancer.
That's one thing you are good at. I'll hand it to you. | | Back to Top | | |
 |  hchcec Registered Member
       Date Joined Aug 2007 Total Posts : 39 | Posted 10/22/2007 4:55 PM (GMT -4) |   | Oh, OK, Pawelski. I'll be happy to do some of the research for you since you're having such trouble. Ol' hchcec can help you out. Don't forget to post this to your hundreds of cancer support sites after you tell the cancer patients about having trouble locating any research to back up your claims that their oncologists are greedy and want nothing more than to make money off cancer patients. :wink:
Recombinant epoetins do NOT stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=16505108&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | | Back to Top | | |
  |  DDye Forum Moderator
       Date Joined Jan 2002 Total Posts : 391 | Posted 10/23/2007 10:44 AM (GMT -4) |   | No enjoyment.
No one has violated Life Extension's forum guidelines. We did at one point decide against personal attacks, but started allowing them again because of a situation where someone had been attacked in the past but had not at that time been able to defend themselves, plus the current members appeared to be ok with it. However, if there is offensive language, repetitiveness, irrelevance, or derogatory one liner posts, these things will be deleted. If either of you do not like the way this thread has developed and find it is offensive to you, email me at ddye@lifeextension.com and it will be removed. | | Back to Top | | |
 | 32 posts in this thread. Viewing Page : 1 2 | | Forum Information | Currently it is Thursday, July 29, 2010 4:11 PM (GMT -4) There are a total of 37,353 posts in 7,621 threads. In the last 3 days there were 3 new threads and 9 reply posts. View Active Threads
| | Who's Online | This forum has 9435 registered members. Please welcome our newest member, alexh1. 16 Guest(s), 0 Registered Member(s) are currently online. Details
|
Forum powered by dotNetBB v2.42EC SP3 dotNetBB © 2000-2010 All Contents Copyright © 2004, Life Extension™. All rights reserved. |
|
|